Brief: SpringWorks Therapeutics FY basic EPS USD -5.15
27/02/2024 11:38
Feb 27 (Reuters) - SpringWorks Therapeutics FY operating expenses USD 348.46 million. * FY operating income USD -343.013 million * FY net income USD -325.104 million * FY basic EPS USD -5.15
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN